The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
IMO if this closes on the high then the push to 20s is inevitable.
I think this year will be the year when significant recurring revenue contracts are signed at which point a true valuation can be assigned (x10 recurring revenue)
Agree that late trade was a buy.
there is certainly accumulation happening in the 28-31p range so that when it does move then to the upside expect it to break resistance point of 32.5 before breaking through the 52w high of 36.50. support is around 28.6p let's hope the sp does not breach that support level.
This seems to be going un-noticed. This IM has taken a 3% stake that may have been accumulated costing more than £1m. Considering their UK income fund @december 2020 had AuM of £8.5m then SBTX is quite a significant investment which leads me to believe they know something.
DYOR
Phermic, so ESRI, the Aussies, Network Rail and the Japanese were all mislead and did not do their DD before partnering or awarding contracts to MNO?
If you own shares then best sell and move on as surely you are in profit otherwise what is the point of posting on this forum. Personally I am happy being up 252% with average purchase price of 4.21. still a hold IMO until I see +20p
Can SNG apply for EUA prior to completion of P3 in the early summer if initial results are shown to be very effective and safe?
I have seen where EUA has been granted with restricted use for other drugs that are still in phase 3.
Dr. Latif does not need to be an expert to in respiratory illness to be qualified to make such comment. The Doctors started with a positive comment but then warned to be cautious based on the experience with hydroxychloroquine.
Anyways, it's not worth discussing the doctor's comments anymore. Would be great to be able to get some feedback from the doctors and nurses treating those patients engaged in the trial.
CityT,
Dr.Latif is not negative but cautious and so should investors. It's easy to get carried away and focus only on the potential good news without considering the possibility of a negative outcome. I have learnt that the hard way with HUR and SOU.
Nevertheless, I am a strong believer in the science and will continue to hold and may just crystalize my huge losses in HUR and SOU to top up a bit more in SNG if I can buy in the 150-160 price range in next few days.
I think the sp will stabilise in the 28-32p range for a few weeks as short term investors take profit and look elsewhere for 8-10 weeks whilst waiting for initial results from the study. Unless there is other news flow before April.
This is actually a good sign of things to come when price drops to fill a buy order. The temptation was there to buy more however I'm happy with my small holdings @21p.
The story has not changed since Friday so hold tight and don't get robbed.
when this was recommended to me it was 21p (up 19%). thought I missed the boat but still bought in.
don't give a hoot about the spike. I bought TSLA at $500 sold at $600 and now it is heading to $900 and that is all in the space of 3-4 weeks. Bought an american biotech JAGX at $1.51 it spiked to $2.20 however did some research so held and now it is $3.78.
As Strictly says, spikes can be either way, look at KODK. Matters if you are a swing trader and/or chartist.
Likewise I bought without knowing too much about the company as it was a chartist tip from a friend. Now I'm up 52% on my small 7k share holding. Considered taking profit but went thru presentation and now I'll hold until at least psoriasis trial completion. If successful then I'd attribute £1/sh for that product line alone not to mention it is a further de-risking on the ladder to a successful multi-product line company which would be very attractive to a sizeable pharma.
DYOR
Munch, thanks for sharing.
Watched the presentation which convinced me to hold rather than take my 50% profit on my small holding of 7k shares.
I think the psoriasis trial is significant and if this step is de-risked then I think there is every chance SBTX gets taken over by a sizeable pharma.